← Leaderboards
Kaku So-Armah
Boston Medical Center
$4,936,976
Attributed
$5,149,319
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,149,319 · 5
By mechanism
P01$4,210,426 · 3
K01$620,379 · 1
R21$318,514 · 1
Top collaborators
- Nana Kwame Ayisi-Boateng2 shared
- Phyllis Tawiah2 shared
Most similar at Boston Medical Center
Same institution · by research overlap
- Neil B Ruderman$15,877,734
- Salomon Amar$19,318,907
- Balz B Frei$9,424,458
- Andrea Coviello$1,290,998
- Noyan Gokce$15,647,950
Others in their field
Top investigators on “Link”
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- David R. Weir · University Of Michigan At Ann Arbor$206,261,870
- Clare E Reimers · Gordon Research Conferences$205,233,456
- Demian A Bailey · Oregon State University$205,233,456
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Greg Ulses · Consortium For Ocean Leadership, Inc$140,113,248
Research focus
LinkAlcoholsBiological MarkersCollaborationsEpidemiologyAgingObservational StudyPersonsDyslipidemiasHeavy DrinkingImmune System DiseasesAlcohol EffectDiagnosisPrimary OutcomeAlcohol ConsumptionX-Ray Computed TomographyHeart DiseasesEventCause Of DeathBiometryCohortFundingCardiovascular DiseasesCardiovascular Disorder Risk
Grant awards (17)
Microbiome, metabolites, and alcohol in HIV to reduce CVD Cohort (META HIV CVD Cohort)$405,435
P01 · FY2025 · AA · contact PI
The Role of Alcohol Use in Lung Disease After Treatment for Active TB Disease Among Persons Living with HIV$270,672
P01 · FY2025 · AA · contact PI
Microbiome, metabolites, and alcohol in HIV to reduce CVD Cohort (META HIV CVD Cohort)$503,806
P01 · FY2024 · AA · contact PI
The Role of Alcohol Use in Lung Disease After Treatment for Active TB Disease Among Persons Living with HIV$491,872
P01 · FY2024 · AA · contact PI
KNUST Aging and HIV Outcomes$175,680
R21 · FY2024 · TW
The Role of Alcohol Use in Lung Disease After Treatment for Active TB Disease Among Persons Living with HIV$452,044
P01 · FY2023 · AA · contact PI
Microbiome, metabolites, and alcohol in HIV to reduce CVD Cohort (META HIV CVD Cohort)$377,630
P01 · FY2023 · AA · contact PI
KNUST Aging and HIV Outcomes$142,834
R21 · FY2023 · TW
The Role of Alcohol Use in Lung Disease After Treatment for Active TB Disease Among Persons Living with HIV$452,220
P01 · FY2022 · AA · contact PI
Microbiome, metabolites, and alcohol in HIV to reduce CVD Cohort (META HIV CVD Cohort)$378,345
P01 · FY2022 · AA · contact PI
The Role of Alcohol Use in Lung Disease After Treatment for Active TB Disease Among Persons Living with HIV$459,981
P01 · FY2021 · AA · contact PI
Microbiome, metabolites, and alcohol in HIV to reduce CVD Cohort (META HIV CVD Cohort)$418,421
P01 · FY2021 · AA · contact PI
Novel Mechanisms Driving Excess Atherosclerotic Cardiovascular Disease Risk in the Context of HIV: The Role of Liver Injury$129,573
K01 · FY2020 · HL · contact PI
Novel Mechanisms Driving Excess Atherosclerotic Cardiovascular Disease Risk in the Context of HIV: The Role of Liver Injury$126,586
K01 · FY2019 · HL · contact PI
Novel Mechanisms Driving Excess Atherosclerotic Cardiovascular Disease Risk in the Context of HIV: The Role of Liver Injury$124,006
K01 · FY2018 · HL · contact PI
Novel Mechanisms Driving Excess Atherosclerotic Cardiovascular Disease Risk in the Context of HIV: The Role of Liver Injury$121,403
K01 · FY2017 · HL · contact PI
Novel Mechanisms Driving Excess Atherosclerotic Cardiovascular Disease Risk in the Context of HIV: The Role of Liver Injury$118,811
K01 · FY2016 · HL · contact PI